Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group Plc LSE:DEMG London Ordinary Share GB0059337583 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.475 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
1.35 1.60 1.475 1.475 1.475
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 2.40 -0.79 -0.15 9
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 1.475 GBX

Deltex Medical (DEMG) Latest News

More Deltex Medical News
Deltex Medical Investors    Deltex Medical Takeover Rumours

Deltex Medical (DEMG) Discussions and Chat

Deltex Medical Forums and Chat

Date Time Title Posts
26/9/202119:18Deltex Medical - a British success story!11,586
20/4/202121:16Deltex Medical-Optimal Growth Stock10,014
21/12/202012:49Deltex Medical - winner or doomed to fail? 414
22/3/201209:04Deltex Medical - Past, Present and Future-
07/12/201111:57Deltex Medical - More key endorsements-

Add a New Thread

Deltex Medical (DEMG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Deltex Medical trades in real-time

Deltex Medical (DEMG) Top Chat Posts

Deltex Medical Daily Update: Deltex Medical Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker DEMG. The last closing price for Deltex Medical was 1.48p.
Deltex Medical Group Plc has a 4 week average price of 1.48p and a 12 week average price of 1.48p.
The 1 year high share price is 2.35p while the 1 year low share price is currently 1.05p.
There are currently 583,572,367 shares in issue and the average daily traded volume is 174,858 shares. The market capitalisation of Deltex Medical Group Plc is £8,607,692.41.
mrc2u: ChasChasWrong board. Nobody cares. Buy some DEMG shares. Be happyMrC
mrc2u: ChasChasDEMG is the flattest of flat lines. Looks like you are in the wrong place and, regardless, we all try to be nice to the Nobster on here. After all, he is only littleMrC
charlescharliesback: Nobbygnome16 Sep '21 - 11:10 - 62561 of 62563 0 0 1 Meanwhile the price action suggests another big dump is coming today. Despite apparently more buys than sells the MMs keep reducing the bid even for small amounts of shares. The distribution continues....
charlescharliesback: Nobbygnome16 Sep '21 - 09:26 - 62477 of 62493 0 3 2 Im convinced the only thing holding the price up is the dubious inside information from Boss man distributed among the Telegram groups. Without that the price would be plummeting......
gbenson1: Ha ha ha, Charly your so transparent, keep your Nobby grievances off this board please, DEMG is going nowhere or maybe perhaps a bid target.
gbenson1: Government has just announced an extra £5.4 bn over next 6 months to clear some of the backlog in procedures due to Covid, surely this should increase the use of/sales for DEMG..
gnnmartin: My feeling is that DEMG have failed to advance for a number of reasons. My remarks may be based on bias and ignorance: I am not a medical man, and my impression is got from attending the AGM over several years, and reading criticisms on bulletin boards. 1: the equipment had a slightly Heath Robinson feel about it. People don't like the idea of having something stuffed down their nose, and anaesthetist did not find it easy to use, and were unconvinced that gave them anything that their professional skill did not. 2: DEMG ran lots of trials to show that their haemodynamic monitor improved recovery times, health outcomes, and reduced recall occurrences, but other companies produced devices to monitor haemodynamics which were much more comfortable for the patient, and less of a fiddle for the anaesthetist to use. Deltex say (and I believe them) that the readings from competing devices are not any where near as accurate and reliable as the readings from the Deltex device. The competing devices quoted the Deltex trials as showing that haemodynamic monitoring was valuable, and anaesthetists thought they might as well give it a try with the more convenient easy to use equipment sold by the competition. The competition did not run any trials (AFAIK), just relied on asserting their equipment was equivalent to DEMG's. 3: The NHS was convinced enough by the Deltex trials to recommend that theatres in the UK employed haemodynamic devices. They did not think it appropriate to say use Deltex devices. Again, when doing something just because you are directed to do so rather than because you believe in it, it is natural to choose the easiest to use and the cheapest. If the anaesthetist did not find the device they used helpful, they were more likely to feel their initial instinct (that they already had the necessary skill to judge the patient's haemodynamics) than they were to feel that some other device might be better. I have come across this several times: if some equipment is mandated, it boosts the sales of the cheapest device, more than the sales of the most effective device. That is why (as I posted above) I am pleased they have worked hard to improve the usability and appearance of their device. As I say, I'm no medical man, I may just be a biased (long standing) shareholder. I don't expect to have anything more to say, so I apologise in advance for failing to answer any more questions: I will probably not be monitoring this BB.
nobbygnome: Yes should be good news for DEMG share price as it will show the true value of a business like this!
mrc2u: Anyway, I have held off on LID's interims compared to DEMG's but LID had sales of 6.2m and DEMG of 1.2m. That is five times higherAnd DEMG only needed to have sold 7,000 less to have rounded to £1.1m which would have made LID over 5.5 times higherI get there are different exposures to surgery between the two but DEMG has a great ICU product especially in ventilated patientsSo, why were LID able to generate £2,698k of monitor sales to the NHS in six months, up 12x on previous fist half? And why were DEMG only able to generate monitor sales of £16k, down from £19k?There was a windfall to be had and LID grabbed it. DEMG totally missed it. DEMG monitor sales in the UK were less than 150th of LIDWhy?Because they have spent over a decade failing to develop a new monitor. Why? What are they doing about it? Who is to blame? Who is sorting it out?But maybe also because they don't know how to sell?What is needed is:New chairNew, smaller, boardNew brokersNew monitorNew marketing storyNew business modelLID has done all the above, DEMG none of it and now DEMG have been shown to have been swimming naked for yearsMrC
schloo: Vega On the remote chance that you really want your question answered DEMG built a robust evidence base of improved outcome and reduced costs after surgery. NICE reviewed the evidence and agreed, giving CardioQ-ODM a whole-hearted & wide ranging recommendation. This led to the NHS deciding to roll out ODM fully at pace and scale across the NHS: this is still the only time that the NHS has decided to roll out a medtech product nationally on the basis of evidence LID has tried to build an evidence base in surgery but has consistently failed. This does not mean its tech doesn't work in surgery, just that it is nothing like as effective as DEMG's So far so good: DEMG was flying in surgery, LID struggling The NHS, after intense lobbying from LID, Edwards & others with inferior technologies, moved from implementing CardioQ-ODM, which had been reviewed by NICE, to ODM in general and then to ODM or similar technologies and then to any technology making marketing claims. Other than CardioQ-ODM they did not, and, disgracefully, still have not actually looked at the evidence nor allowed NICE to do so This gave LID a huge leg up. The LID product, or at least the LidcoRapid, is much easier to use than ODM so anybody who believed they were the same would be justified in choosing the easy one rather than the one requiring more effort, skill and interpretation. Much easier for LID or Edwards sales reps to sell their kit as being as good as ODM when the NHS was telling them, wrongly, that it was the same thing Then the NHS pulled its national roll-out programme anyway for idiotic bureaucratic reasons, causing a backlash against DEMG from doctors who had not liked being told to change their practice and blamed DEMG for a cynical exploitation of its (objective) evidence base. Nobody else was blamed because they hadn't exploited evidence they didn't have There are other layers to the shambles but, basically, LID got lucky while DEMG got shafted HOWEVER that is in the past. DEMG now sells the same entry level tech as LID but also offers a good non-invasive impedance tech as well as ODM off the same platform. Once they have a shiny new box (soon) DEMG should start to regain share quite rapidly More importantly, it can only be a matter of time before someone, somewhere looks objectively at the LID evidence during surgery. They have done at least 10 studies and have not got one single positive result. DEMG have done over 20 and have over 20 positive results Long term it really does matter that ODM is superior - avoidable complications after surgery kill in CoVid type numbers every year so this will one day get the attention it merits and LID's bluff will be well & truly called and whoever owns DEMG will make monstrous returns That said, I think LID has a good monitoring technology, some well designed products and is well run these days by a good team. I own some shares, have doubled my money recently and think there is still plenty of upside. DEMG could and should learn from them. However, I don't think they are a great takeover candidate because their technology is not that well differentiated so they are selling revenues and profits more than DEMG who are selling unique and proven tech for which there is a clear and massive global need. I.e. any of Edwards, Baxter, Medtronic, J&J and so on could do far far more with DEMG than LID. I own a lot more of DEMG than I do of LID Hope that helps Schloo
Deltex Medical share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Deltex Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210927 01:18:59